Efficacy and safety of different chemotherapy regimens in patients with disseminated pancreatic cancer over 65 years old

Aim. To evaluate the effectiveness and tolerability of systemic chemotherapy in elderly patients with metastatic pancreatic cancer (mPC) in real clinical practice.

Materials and methods. The study included patients with mPC over 65 years of age who received first-line chemotherapy at the N. N. Blokhin National Medical Research Center of Oncology for the period from 2004 to 2023. Any previous antitumor chemotherapy for mPC was an exclusion criterion. The primary endpoint was 1-year overall survival (OS), and the secondary endpoints were ORR, median progression-free survival, median OS, chemotherapy tolerability.

Results. The study included 148 patients aged 65 to 86 years with mPC who received first-line chemotherapy. Median progression-free survival among the entire population was 5.2 months. One-year OS among all patients was 32 %. The 1-year OS in mFOLFIRINOX group was 43.4 % and in gemcitabine group – 19.6 %. In a subgroup analysis, median OS with combination treatment was higher than in the gemcitabine monotherapy group (median OS 8.4 months vs. 6.8 months, p = 0.009). Patients with ECOG 2–3 also benefited from combination chemotherapy. Median OS was 8.9 months versus 3.9 months in gemcitabine (p = 0.008). The frequency of an objective response with triple chemotherapy was 66.1 %. In 30.8 % of cases, grade 3–4 neutropenia developed with mFOLFIRINOX, but febrile neutropenia developed only in three patients (5.8 %). The incidence of grade 3–4 adverse events was low, and these chemotherapy regimens were well tolerated.

Conclusion. Conducting a triple chemotherapy regimen in elderly patients with mPC is an effective treatment option with an acceptable range of toxicity. 

1. International Agency for Research on Cancer. Available at: https:// gco.iarc.fr/today/data/factsheets/populations/900-world-factsheets.pdf

2. National Cancer Institute. Available at: https://seer.cancer.gov/ statfacts/html/pancreas.html

3. Conroy T., Desseigne F., Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817–25. DOI: 10.1056/NEJMoa1011923

4. Von Hoff D.D., Ervin T., Arena F.P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691–703. DOI: 10.1056/NEJMoa1304369

5. Common Terminology Criteria for Adverse Events – CTCAE v4.0, 2009. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_ QuickReference_8.5x11.pdf

6. King G., Ittershagen S., He L. et al. Treatment patterns in US patients receiving first-line and second-line therapy for metastatic pancreatic ductal adenocarcinoma in the real world. Adv Ther 2022;39(12):5433–52. DOI: 10.1007/s12325-022-02317-9

7. Klein-Brill A., Amar-Farkash Sh., Lawrence G. et al. Real-world data comparing FOLFIRINOX versus gemcitabine nab-paclitaxel as first-line treatment of metastatic pancreatic ductal adenocarcinoma patients in the United States. J Clin Oncol 2022;40(16_suppl):e16271. DOI: 10.1200/JCO.2022.40.16_suppl.e16271

8. Elias R., Cockrum P., Surinach A. et al. Real-world impact of age at diagnosis on treatment patterns and survival outcomes of patients with metastatic pancreatic ductal adenocarcinoma. Oncologist 2022;27(6):469–75. DOI: 10.1093/oncolo/oyac028

9. Conroy T., Tempero M. Proc ASCO 2010; Abstract 4010. Available at: https://www.researchtopractice.com/sites/default/files/mobile_ audio/feed/5MJC10/8/5MJCMT810_1_Conroy.pdf

10. Jooste V., Bengrine-Lefevre L., Manfredi S. et al. Management and outcomes of pancreatic cancer in french real-world clinical practice. Cancers (Basel) 2022;14(7):1675. DOI: 10.3390/cancers14071675

11. Sarkar R.R., Matsuno R., Murphy J.D. Pancreatic cancer: survival in clinical trials versus the real world. J Clin Oncol 2016; 34(4_suppl):216. DOI: 10.1200/jco.2016.34.4_suppl.216

12. Taieb J., Seufferlein T., Reni M. et al. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a realworld study in Europe. BMC Cancer 2023;23(1):877. DOI: 10.1186/s12885-023-11377-1

13. Bachet J.B., Mitry E., Lièvre A. et al. Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients. Gastroenterol Clin Biol 2009;33(10–11): 1036–44. DOI: 10.1016/j.gcb.2009.03.017

14. Gränsmark E., Bågenholm B.N., Blomstrand H. et al. Real world evidence on second-line palliative chemotherapy in advanced pancreatic cancer. Front Oncol 2020;10:1176. DOI: 10.3389/fonc.2020.01176

15. Chikhareva Ya.E., Fedyanin M.Yu., Bazin I.S. et al. Systemic therapy for metastatic pancreatic cancer. Zlokachestvennye opukholi = Malignant Tumours 2023;13(4):60–8. DOI: 10.18027/2224-5057-2023-13-4-60-68

16. Canton С., Boussari O., Boulin M. et al. Impact of G-CSF prophylaxis on chemotherapy dose-intensity, link between doseintensity and survival in patients with metastatic pancreatic adenocarcinoma. Oncologist 2022;27(7):e571–9. DOI: 10.1093/oncolo/oyac055